Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
22.64
+0.57 (2.56%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neurogene Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -53.25 | -36.32 | -55.19 | -50.52 |
| Depreciation & Amortization | 3.28 | 3.3 | 3.2 | 0.95 |
| Loss (Gain) From Sale of Investments | -1.57 | -0.11 | - | - |
| Stock-Based Compensation | 6.19 | 1.42 | 1.25 | 0.9 |
| Other Operating Activities | -15.51 | -15.69 | 0.61 | 0.68 |
| Change in Accounts Payable | -0.5 | 0.67 | -3.61 | 2.98 |
| Change in Other Net Operating Assets | -8.81 | -4.69 | 0.91 | -1.39 |
| Operating Cash Flow | -70.08 | -51.42 | -52.82 | -46.4 |
| Capital Expenditures | -0.82 | -0.32 | -2.23 | -18.37 |
| Cash Acquisitions | 20.96 | 20.96 | - | - |
| Investment in Securities | -16.95 | 5 | - | - |
| Investing Cash Flow | 3.19 | 25.64 | -2.23 | -18.37 |
| Long-Term Debt Repaid | - | -0.03 | -0 | - |
| Net Debt Issued (Repaid) | -0.05 | -0.03 | -0 | - |
| Issuance of Common Stock | 1.19 | 0.17 | 0.07 | 0.29 |
| Other Financing Activities | 87.16 | 92.34 | - | - |
| Financing Cash Flow | 88.3 | 92.48 | 66.53 | 51.06 |
| Net Cash Flow | 21.41 | 66.7 | 11.48 | -13.71 |
| Free Cash Flow | -70.9 | -51.74 | -55.05 | -64.77 |
| Free Cash Flow Per Share | -5.51 | -11.11 | -139.54 | -15.99 |
| Cash Interest Paid | 0.01 | 0.01 | 0 | - |
| Levered Free Cash Flow | -35.53 | -16.42 | -36.68 | - |
| Unlevered Free Cash Flow | -35.52 | -16.42 | -36.68 | - |
| Change in Net Working Capital | -3.16 | -13.93 | 3.58 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.